NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67386-0811-55 | 67386-0811 | Dactinomycin | Cosmegen | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Dec. 10, 1964 | April 23, 2013 | No Longer Used | |
67457-0513-05 | 67457-0513 | Dactinomycin | Dactinomycin | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Jan. 1, 2018 | In Use | |
67457-0513-99 | 67457-0513 | Dactinomycin | Dactinomycin | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Jan. 1, 2018 | In Use | |
00703-3154-01 | 00703-3154 | Bleomycin | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | June 30, 2000 | July 31, 2023 | No Longer Used |
00703-3155-01 | 00703-3155 | Bleomycin | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | June 30, 2000 | Aug. 31, 2023 | No Longer Used |
42658-0008-01 | 42658-0008 | Dactinomycin | Dactinomycin | 0.5 mg/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | May 8, 2024 | In Use | |
67457-0928-02 | 67457-0928 | Dactinomycin | Dactinomycin | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | June 20, 2019 | In Use | |
55292-0811-55 | 55292-0811 | Dactinomycin | Cosmegen | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Dec. 10, 1964 | Nov. 30, 2024 | In Use |
66993-0489-35 | 66993-0489 | Dactinomycin | Dactinomycin | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Dec. 4, 2017 | Nov. 30, 2024 | In Use |
00187-1221-03 | 00187-1221 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | Nov. 1, 2009 | Nov. 13, 2017 | No Longer Used |
00187-1231-50 | 00187-1231 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | March 9, 2020 | In Use | |
00037-1221-50 | 00037-1221 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | March 1, 2010 | March 31, 2020 | No Longer Used |
60687-0375-01 | 60687-0375 | DRONABINOL | DRONABINOL | 2.5 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | July 16, 2018 | Sept. 30, 2025 | In Use |
60687-0375-21 | 60687-0375 | DRONABINOL | DRONABINOL | 2.5 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | March 31, 2024 | In Use | |
68001-0480-22 | 68001-0480 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 14, 2020 | In Use | |
68001-0480-35 | 68001-0480 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 14, 2020 | In Use | |
68083-0381-01 | 68083-0381 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
70700-0169-22 | 70700-0169 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 4, 2020 | In Use | |
68083-0382-01 | 68083-0382 | Irinotecan hydrochloride | Irinotecan hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
70700-0170-22 | 70700-0170 | Irinotecan hydrochloride | Irinotecan hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
00007-4201-01 | 00007-4201 | Topotecan Hydrochloride | Hycamtin | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 7, 1996 | July 31, 2018 | No Longer Used |
00007-4205-11 | 00007-4205 | Topotecan Hydrochloride | Hycamtin | 0.25 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | Sept. 16, 2008 | Dec. 31, 2017 | No Longer Used |
00007-4207-11 | 00007-4207 | Topotecan Hydrochloride | Hycamtin | 1.0 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | Sept. 16, 2008 | Jan. 31, 2018 | No Longer Used |
00069-0075-01 | 00069-0075 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 29, 2012 | Dec. 31, 2016 | No Longer Used |
Found 10,000 results in 7 milliseconds — Export these results